O
OncoMyx Therapeutics
Gene therapy with myxoma viruses
About OncoMyx Therapeutics
OncoMyx Therapeutics operates in the biotechnology sector, focusing on developing oncolytic immunotherapies to treat cancer. The company leverages the myxoma virus, a type of virus that selectively infects and kills cancer cells while sparing normal cells. This innovative approach aims to enhance the body's immune response against tumors. OncoMyx primarily serves the healthcare market, targeting oncology patients and medical professionals seeking advanced cancer treatments. The business model revolves around research and development, clinical trials, and eventual commercialization of their therapies. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company is positioned to address a significant unmet need in cancer treatment, offering a novel solution that could complement existing therapies and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Tempe, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 72.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $50M | $200M | Boehringer Ingelheim Venture Fund · Xeraya Capital · Delos Capital · City Hill Ventures | ↗ |
| SERIES AOther financing | Apr 2019 | $25M | $100M | Undisclosed | — |
Growth signals
Latest recorded traffic for OncoMyx Therapeutics is 240 monthly website visits, down 61.9% over the last three months. OncoMyx Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OncoMyx Therapeutics in the Tempe ecosystem
The OncoMyx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
B Capital
Lumira Ventures
Boehringer Ingelheim Venture Fund
Xeraya Capital
Delos Capital
City Hill Ventures- LCLYZZ Capital
Korea Investment Partners
Madison Partners
Other known investors1 additional known investor
Arizona State University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoMyx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoMyx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










